Delving into the Latest Updates on JNJ-64300535 with Synapse

Overview

Basic Info

Drug Type

DNA vaccine, Therapeutic vaccine

Synonyms

Target-

Mechanism

Immunostimulants

Therapeutic Areas

Infectious DiseasesDigestive System Disorders

Active Indication

Hepatitis B, ChronicHepatitis B

Inactive Indication-

Originator Organization

Ichor Medical Systems, Inc.

Active Organization

Janssen Research & Development LLC

Ichor Medical Systems, Inc.

Inactive Organization

Janssen Sciences Ireland UC

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

A First-In-Human, Double-Blind, Randomized, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, Reactogenicity, and Immunogenicity of JNJ-64300535, a DNA Vaccine, Administered by Electroporation-Mediated Intramuscular Injection, in Participants With Chronic Hepatitis B Who Are on Stable Nucleos(T)Ide Therapy and Virologically Suppressed

The purpose of this study is to evaluate the safety, tolerability, and reactogenicity of escalating doses of JNJ-64300535 delivered via electroporation-mediated intramuscular injection in nucleos(t)ide analogs (NA)-treated chronic hepatitis B (CHB) participants.

Start Date18 Apr 2018

Sponsor / Collaborator

Janssen Sciences Ireland UC

100 Clinical Results associated with JNJ-64300535

Login to view more data

100 Translational Medicine associated with JNJ-64300535

Login to view more data

100 Patents (Medical) associated with JNJ-64300535

Login to view more data

100 Deals associated with JNJ-64300535

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hepatitis B	Phase 1	-	Ichor Medical Systems, Inc.	-
Hepatitis B, Chronic	Discovery	BE	Janssen Sciences Ireland UC	18 Apr 2018
Hepatitis B, Chronic	Discovery	DE	Janssen Sciences Ireland UC	18 Apr 2018
Hepatitis B, Chronic	Discovery	GB	Janssen Sciences Ireland UC	18 Apr 2018